Pharvaris Phase 3 Lancet Trial Proves Oral Deucrictibant Stops HAE Attacks in 1.28 Hours.

Good morning, HealthTech insiders. An oral medicine that starts easing symptoms in a median of 1.28 hours deserves attention. Pharvaris' newly published Phase 3 results put oral deucrictibant firmly in the conversation about treating hereditary angioedema. The distinction matters: that figure measures symptom relief; complete resolution took longer. But for a patient deciding how to treat an unpredictable attack, another effective oral option could make a real difference.

Elsewhere, AbbVie has earned two FDA Breakthrough Therapy Designations for an experimental cancer drug, while Daxor is showcasing a faster blood volume analyzer alongside research in advanced heart failure. Today's stories ask what better treatment delivery and better measurement could change in care, and what the evidence still needs to establish.

In today's Signal:

• Another oral HAE option advances: Pharvaris' RAPIDe-3 results appear in The Lancet, with faster symptom relief than placebo. Deucrictibant remains under regulatory review.

• AbbVie's ADC earns two designations: Telisotuzumab adizutecan receives Breakthrough status in defined colorectal and lung cancer settings; it remains investigational.

• Daxor takes blood volume analysis to HFSA: A faster lab-based analyzer and two scheduled research presentations focus on complex heart failure and mechanical circulatory support.

• Follow the Money: An $86.6M announced PIPE, a $58M biotech launch, $38M across two AI funding rounds, and a $33M microbiome Series B.

In partnership with

What if AI made us prove we’re creative?

This year AI shook up creative strategy. Most teams are still working like it didn't.

Ari Murray, Chief Digital Officer at Salt and Stone sits down with Bryan Harvey, Head of Brand at Hightouch, for an honest conversation about what's breaking on creative teams right now, how the roles are changing, and what a day looks like when creatives spend it on ideas, concepts, and craft while agents handle the manual execution.

Leave with new insights from 3 experts in the field and 5 prompts to instantly improve your creative output.

Reserve your seat

RARE DISEASE & CLINICAL PHARMACOLOGY
1. Pharvaris Publishes Phase 3 Oral Deucrictibant Results in The Lancet

Pharvaris announced on October 8 that RAPIDe-3 results were published in The Lancet. The trial compared a 20 mg immediate-release capsule of deucrictibant, an oral bradykinin B2 receptor antagonist, with placebo for hereditary angioedema attacks.

The details:

• Relief versus resolution: Median time to onset of symptom relief was 1.28 hours; complete symptom resolution was 11.95 hours. The study met its primary and all 11 secondary endpoints.

• The evidence base: The trial randomized 134 participants; 88 participants with paired treated attacks formed the primary efficacy analysis. Pharvaris reported a well-tolerated safety profile. Findings in small subgroups need cautious interpretation.

• The regulatory position: The on-demand formulation remains investigational. Its FDA target action date is April 23, 2027; an action date is not a promised approval.

The Signal: Oral on-demand HAE treatment is already available in the U.S. through Ekterly. Deucrictibant could broaden patient choice through a different mechanism if approved. Its placebo-controlled result does not establish superiority to another oral medicine or an injectable treatment.

TARGETED ONCOLOGY & ANTIBODY DRUG CONJUGATES
2. AbbVie's Temab-A Receives Two FDA Breakthrough Therapy Designations

AbbVie announced the designations on October 7 for telisotuzumab adizutecan (Temab-A; ABBV-400), an investigational c-Met-directed antibody-drug conjugate carrying a topoisomerase 1 inhibitor payload.

The details:

• Colorectal cancer: The designation covers combination treatment with bevacizumab in refractory metastatic disease after specified prior therapies, including anti-EGFR treatment when indicated.

• Lung cancer: The monotherapy designation covers previously treated, locally advanced or metastatic EGFR wild-type, c-Met protein-expressing, nonsquamous NSCLC after platinum chemotherapy and anti-PD-(L)1 therapy.

• What the milestone means: Breakthrough status supports expedited development and review. It is not approval, and the designations were primarily based on the first-in-human M21-404 study. AbbVie says the program already includes Phase 3 and Phase 2/3 studies.

The Signal: The same ADC is advancing in two difficult treatment settings, but each needs its own evidence of durable benefit and acceptable safety. These designations strengthen the development case; they do not settle comparative effectiveness or establish a new standard of care.

CARDIOLOGY & BLOOD VOLUME DIAGNOSTICS
3. Daxor Showcases a Faster Blood Volume Analyzer at HFSA

Daxor's October 1 announcement described its participation at HFSA's October 9-12 meeting in Phoenix and two investigator ePosters scheduled for October 10. The company is featuring its next-generation lab-based Blood Volume Analyzer. The FDA cleared the BVA-200 in August 2025 for laboratory use in adults.

The details:

• The workflow claim: Daxor reports three-times-faster operation, half the blood draw volume and greater than 95% measurement accuracy versus its predecessor platform.

• The research focus: The scheduled ePosters address blood volume analysis in LVAD and total artificial heart patients, and variation in red cell and plasma volume in advanced heart failure.

• The evidence boundary: The announcement does not provide study sizes, comparative outcome data, or quantified reductions in readmissions, suction events or hospital stay. Those results require the actual abstracts and full studies.

The Signal: Blood volume measurement could help explain why a low hematocrit or a congested patient needs closer assessment. Its adoption case depends on whether the information changes treatment usefully within a workable clinical workflow. Faster analysis alone does not demonstrate better outcomes.

👀 WHAT WE'RE WATCHING NEXT

1. Pharvaris: Regulatory decisions and proposed labeling for on-demand use; detailed follow-up on CHAPTER-3 prevention results, already announced September 8.

2. AbbVie: Enrollment and results from the existing late-stage program, with attention to duration of response, survival, patient selection and safety.

3. Daxor: Full HFSA abstracts, reproducible workflow results and controlled evidence linking measurement-guided treatment to outcomes.

💰 FOLLOW THE MONEY

The deals:

• ADC Therapeutics: Announced an $86.6M PIPE on October 8 as part of a broader restructuring. Closing is expected October 22, subject to conditions. Proceeds support ZYNLONTA studies and the balance sheet; expected runway extends into 2029.

• RougeTx: Launched October 6 with a $58M Series A to advance RTX-001 toward first-in-human development in hereditary hemorrhagic telangiectasia. Its lead program is a potential oral small-molecule treatment.

• Healthleap: Announced $38M in combined seed and Series A funding from Sequoia, First Round and Hummingbird. Its inpatient screening platform began with malnutrition and is expanding to other underdiagnosed conditions.

• Tiny Health: Its September 29 announcement reported a $33M Series B led by B Capital, bringing cumulative funding to $46M. The company offers gut and vaginal microbiome testing across the lifespan.: $70M Series C led by NewView Capital for ambient senior care AI at a $500M+ valuation.

The pattern: These amounts sum to $215.6M, but they combine an announced financing, combined rounds and a late-September raise. They are a financing roundup, not cash closed today. The businesses also face different tests: clinical development, balance-sheet execution, hospital adoption and evidence for microbiome-guided care.

📆 UPCOMING HEALTHTECH EVENTS

• World Health Summit: October 11-13 | Berlin and online. Global health policy, research and cooperation under the theme From Crisis to Resilience: Innovating for Health.

• Frontiers Health: October 20-21 | bcc Berlin Congress Center, Berlin. Digital health, life sciences, investment and the practical adoption of innovation.

• Global Health Exhibition: October 26-29 | Riyadh Exhibition & Convention Centre, Malham, Saudi Arabia. Healthcare transformation, medical technology and investment.

🛠️ Trending HealthTech AI Tools

• MyoVista wavECG / MyoVista Insights: HeartSciences' October 6 clearance covers the resting ECG device, not its impaired cardiac relaxation AI algorithm. Insights is a separate platform for ECG workflows and partner algorithms; commercialization of wavECG has no committed timeline.

• Bayesian Health Sepsis Flagging Device: FDA-cleared AI supports early detection or risk prediction of sepsis developing within 24 hours in adults in acute care. That prediction window does not mean every case is detected 24 hours earlier. Clinical assessment remains essential; NTAP applies to qualifying inpatient use.

• Aidoc CARE Body CT Multi-Triage: FDA-cleared software flags suspected urgent findings on chest, abdominal and pelvic CT for workflow prioritization. NTAP eligibility began October 1 for qualifying Medicare fee-for-service inpatient cases; it is not automatic payment for every scan.

🛠️ Trending HealthTech AI Startups

• Pharvaris: Public, late-stage biopharma developing oral deucrictibant for on-demand treatment and prevention of HAE attacks.

• Daxor: Public medtech company commercializing blood volume analysis. Its analyzers measure blood volume components to inform clinical assessment.

• Tiny Health: Private microbiome testing company expanding research and practitioner services. TinyAI uses a dataset of nearly 200,000 microbiome profiles, according to the company; that scale does not by itself establish clinical utility.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

• What Deucrictibant Could Add to Oral HAE Treatment
  The trial endpoints, existing oral competition and access questions behind the latest HAE result.

• What Two Breakthrough Designations Mean for AbbVie
  Why expedited development matters, and which clinical outcomes still determine Temab-A's prospects.

• How Blood Volume Analysis Could Inform Heart Failure Care
  The measurement problem, workflow considerations and evidence needed to establish clinical value.

That's it for today!

Better care can start with changing how treatment reaches a patient, or what clinicians can measure before making a decision.

Pharvaris is advancing another oral option for unpredictable HAE attacks. AbbVie is testing a targeted approach in cancers that have progressed despite treatment. Daxor is bringing more detailed blood volume measurement into the heart failure conversation.

Each offers a practical possibility: easier administration, another treatment option, or better information when care gets complicated.

The next question is how much those advances change life for patients.

Can they deliver meaningful benefits, reach the people who need them, and fit into the realities of everyday care? That is where today's promising milestones will face their biggest test.

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.